We have already shown that the mutant-p53 breast cancer cell line MDA-MB-231 is susceptible to extract treatment and that inhibition of extract-induced p53 expression in MCF-7 cells associates with improved cell survival in response to extract but does not abrogate extract effect completely. This evidence concerns the gene TP53 and breast cancer.